메뉴 건너뛰기




Volumn 6, Issue 10, 2015, Pages 8366-8376

Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy

Author keywords

Blood brain barrier; Brain metastasis; Gefitinib; Non small cell lung cancer; Whole brain radiation therapy

Indexed keywords

GEFITINIB; VANDETANIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

EID: 84928399519     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3187     Document Type: Article
Times cited : (94)

References (44)
  • 2
    • 2142813718 scopus 로고    scopus 로고
    • Temporal and gender-related trends in brain metastases from lung and breast cancer
    • Yawn BP, Wollan PC, Schroeder C, Gazzuola L, Mehta M. Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med. 2003; 86:32-37.
    • (2003) Minn Med , vol.86 , pp. 32-37
    • Yawn, B.P.1    Wollan, P.C.2    Schroeder, C.3    Gazzuola, L.4    Mehta, M.5
  • 3
    • 0032959628 scopus 로고    scopus 로고
    • Surgical strategies for metastatic lung cancer
    • Olak J. Surgical strategies for metastatic lung cancer. Surg Oncol Clin N Am. 1999; 8:245-257.
    • (1999) Surg Oncol Clin N Am , vol.8 , pp. 245-257
    • Olak, J.1
  • 4
    • 84857627477 scopus 로고    scopus 로고
    • Treatment of brain metastases: chemotherapy
    • Grimm SA. Treatment of brain metastases: chemotherapy. Curr Oncol Rep. 2012; 14:85-90.
    • (2012) Curr Oncol Rep , vol.14 , pp. 85-90
    • Grimm, S.A.1
  • 6
    • 0025615466 scopus 로고
    • Influence of radiation on the blood-brain barrier and optimum time of chemotherapy
    • Qin DX, Zheng R, Tang J, Li JX, Hu YH. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990; 19:1507-1510.
    • (1990) Int J Radiat Oncol Biol Phys , vol.19 , pp. 1507-1510
    • Qin, D.X.1    Zheng, R.2    Tang, J.3    Li, J.X.4    Hu, Y.H.5
  • 8
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet. 2005; 366:1527-1537.
    • (2005) Lancet , vol.366 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3    Rodrigues Pereira, J.4    Ciuleanu, T.5    von Pawel, J.6    Thongprasert, S.7    Tan, E.H.8    Pemberton, K.9    Archer, V.10    Carroll, K.11
  • 12
    • 34548049302 scopus 로고    scopus 로고
    • Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain
    • Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007; 57:359-364.
    • (2007) Lung Cancer , vol.57 , pp. 359-364
    • Wu, C.1    Li, Y.L.2    Wang, Z.M.3    Li, Z.4    Zhang, T.X.5    Wei, Z.6
  • 17
    • 4143110253 scopus 로고    scopus 로고
    • Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
    • Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004; 15:1042-1047.
    • (2004) Ann Oncol , vol.15 , pp. 1042-1047
    • Ceresoli, G.L.1    Cappuzzo, F.2    Gregorc, V.3    Bartolini, S.4    Crino, L.5    Villa, E.6
  • 18
    • 84865197331 scopus 로고    scopus 로고
    • Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
    • Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012; 77:556-560.
    • (2012) Lung Cancer , vol.77 , pp. 556-560
    • Park, S.J.1    Kim, H.T.2    Lee, D.H.3    Kim, K.P.4    Kim, S.W.5    Suh, C.6    Lee, J.S.7
  • 20
    • 67449122414 scopus 로고    scopus 로고
    • Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population
    • Ma SL, Xu YP, Deng QH, Yu XM. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer. 2009; 65:198-203.
    • (2009) Lung Cancer , vol.65 , pp. 198-203
    • Ma, S.L.1    Xu, Y.P.2    Deng, Q.H.3    Yu, X.M.4
  • 21
    • 0036632353 scopus 로고    scopus 로고
    • Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review)
    • van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep. 2002; 9:683-688.
    • (2002) Oncol Rep , vol.9 , pp. 683-688
    • van Vulpen, M.1    Kal, H.B.2    Taphoorn, M.J.3    El-Sharouni, S.Y.4
  • 22
    • 33749046899 scopus 로고    scopus 로고
    • Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    • Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Janne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006; 24:4517-4520.
    • (2006) J Clin Oncol , vol.24 , pp. 4517-4520
    • Jackman, D.M.1    Holmes, A.J.2    Lindeman, N.3    Wen, P.Y.4    Kesari, S.5    Borras, A.M.6    Bailey, C.7    de Jong, F.8    Janne, P.A.9    Johnson, B.E.10
  • 23
    • 44449131799 scopus 로고    scopus 로고
    • Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene
    • Fukuhara T, Saijo Y, Sakakibara T, Inoue A, Morikawa N, Kanamori M, Nakashima I, Nukiwa T. Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med. 2008; 214:359-363.
    • (2008) Tohoku J Exp Med , vol.214 , pp. 359-363
    • Fukuhara, T.1    Saijo, Y.2    Sakakibara, T.3    Inoue, A.4    Morikawa, N.5    Kanamori, M.6    Nakashima, I.7    Nukiwa, T.8
  • 26
    • 77954427100 scopus 로고    scopus 로고
    • Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer
    • Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010; 5:950-955.
    • (2010) J Thorac Oncol , vol.5 , pp. 950-955
    • Togashi, Y.1    Masago, K.2    Fukudo, M.3    Terada, T.4    Fujita, S.5    Irisa, K.6    Sakamori, Y.7    Kim, Y.H.8    Mio, T.9    Inui, K.10    Mishima, M.11
  • 29
    • 84916879495 scopus 로고    scopus 로고
    • The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from nonsmall-cell lung cancer
    • Deng Y, Feng W, Wu J, Chen Z, Tang Y, Zhang H, Liang J, Xian H, Zhang S. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from nonsmall-cell lung cancer. Mol Clin Oncol. 2014; 2:116-120.
    • (2014) Mol Clin Oncol , vol.2 , pp. 116-120
    • Deng, Y.1    Feng, W.2    Wu, J.3    Chen, Z.4    Tang, Y.5    Zhang, H.6    Liang, J.7    Xian, H.8    Zhang, S.9
  • 31
    • 0141450250 scopus 로고    scopus 로고
    • Influence of radiation on the blood-brain barrier and optimum time of chemotherapy
    • Qin D, Zheng R, Ma J, Xiao J, Tang Z. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999; 21:307-310.
    • (1999) Zhongguo Yi Xue Ke Xue Yuan Xue Bao , vol.21 , pp. 307-310
    • Qin, D.1    Zheng, R.2    Ma, J.3    Xiao, J.4    Tang, Z.5
  • 33
    • 0031005544 scopus 로고    scopus 로고
    • Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents
    • Qin D, Ma J, Xiao J, Tang Z. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol. 1997; 20:263-265.
    • (1997) Am J Clin Oncol , vol.20 , pp. 263-265
    • Qin, D.1    Ma, J.2    Xiao, J.3    Tang, Z.4
  • 35
    • 0037142314 scopus 로고    scopus 로고
    • A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials
    • Jones HK, Stafford LE, Swaisland HC, Payne R. A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. J Pharm Biomed Anal. 2002; 29:221-228.
    • (2002) J Pharm Biomed Anal , vol.29 , pp. 221-228
    • Jones, H.K.1    Stafford, L.E.2    Swaisland, H.C.3    Payne, R.4
  • 38
    • 67049096054 scopus 로고    scopus 로고
    • Radiation-induced astrogliosis and bloodbrain barrier damage can be abrogated using anti-TNF treatment
    • Wilson CM, Gaber MW, Sabek OM, Zawaski JA, Merchant TE. Radiation-induced astrogliosis and bloodbrain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys. 2009; 74:934-941.
    • (2009) Int J Radiat Oncol Biol Phys , vol.74 , pp. 934-941
    • Wilson, C.M.1    Gaber, M.W.2    Sabek, O.M.3    Zawaski, J.A.4    Merchant, T.E.5
  • 40
    • 40749142429 scopus 로고    scopus 로고
    • Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response
    • Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC. Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res. 2008; 14:162-168.
    • (2008) Clin Cancer Res , vol.14 , pp. 162-168
    • Gow, C.H.1    Chien, C.R.2    Chang, Y.L.3    Chiu, Y.H.4    Kuo, S.H.5    Shih, J.Y.6    Chang, Y.C.7    Yu, C.J.8    Yang, C.H.9    Yang, P.C.10
  • 41
    • 77956060394 scopus 로고    scopus 로고
    • High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
    • Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010; 99:283-286.
    • (2010) J Neurooncol , vol.99 , pp. 283-286
    • Clarke, J.L.1    Pao, W.2    Wu, N.3    Miller, V.A.4    Lassman, A.B.5
  • 43
    • 84856235127 scopus 로고    scopus 로고
    • Outcome, quality of life and cognitive function of patients with brain metastases from nonsmall cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomid. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
    • Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, et al. Outcome, quality of life and cognitive function of patients with brain metastases from nonsmall cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer. 2012; 48:377-384.
    • (2012) Eur J Cancer , vol.48 , pp. 377-384
    • Pesce, G.A.1    Klingbiel, D.2    Ribi, K.3    Zouhair, A.4    von Moos, R.5    Schlaeppi, M.6    Caspar, C.B.7    Fischer, N.8    Anchisi, S.9    Peters, S.10    Cathomas, R.11    Bernhard, J.12    Kotrubczik, N.M.13    D'Addario, G.14    Pilop, C.15    Weber, D.C.16
  • 44
    • 10444237217 scopus 로고    scopus 로고
    • Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity
    • Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer. 2005; 47:129-138.
    • (2005) Lung Cancer , vol.47 , pp. 129-138
    • Chiu, C.H.1    Tsai, C.M.2    Chen, Y.M.3    Chiang, S.C.4    Liou, J.L.5    Perng, R.P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.